Natco Pharma locked at 20% upper circuit as partner Mylan gets USFDA nod for multiple sclerosis drug
NewsNews / News 7 years ago 613 Views comments

The firm projects PAT CAGR of 28 percent over three years.
News / News 7 years ago 613 Views comments
Comments